Abu Esba Laila Carolina, Alqahtani Rahaf Ali, Thomas Abin, Shamas Nour, Alswaidan Lolowa, Mardawi Gahdah
Pharmaceutical Care Department, Ministry of the National Guard, Health Affairs, Riyadh, Saudi Arabia.
King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Infect Dis Ther. 2021 Mar;10(1):253-268. doi: 10.1007/s40121-020-00363-w. Epub 2020 Nov 2.
Ibuprofen disappeared from the pharmacy shelves during the 2019 coronavirus (COVID-19) pandemic. However, a while later, information circulated that ibuprofen should be avoided as it could worsen COVID-19 symptoms. The aim of our study was to assess the association of acute and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) with worse COVID-19 outcomes.
We did a prospective cohort study between April 12 and June 1, 2020. Adults consecutively diagnosed with COVID-19 were included. Information on NSAID use was collected through a telephone questionnaire, and patients were followed up for COVID-19 infection outcomes, including death, admission, severity, time to clinical improvement, oxygen requirement and length of stay.
Acute use of ibuprofen was not associated with a greater risk of mortality relative to non-use (adjusted hazard ratio [HR] 0.632 [95% CI 0.073-5.441; P = 0.6758]). Chronic NSAID use was also not associated with a greater risk of mortality (adjusted HR 0.492 [95% CI 0.178-1.362; P = 0.1721]). Acute ibuprofen use was not associated with a higher risk of admission compared to non-NSAID users (adjusted odds ratio OR 1.271; 95% CI 0.548-2.953). NSAID users did not have a significantly longer time to clinical improvement or length of stay.
Acute or chronic use of ibuprofen and other NSAIDs was not associated with worse COVID-19 disease outcomes.
在2019冠状病毒病（COVID-19）大流行期间，布洛芬从药店货架上消失了。然而，一段时间后，有消息流传称应避免使用布洛芬，因为它可能会使COVID-19症状恶化。我们研究的目的是评估非甾体抗炎药（NSAIDs）的急性和慢性使用与更差的COVID-19结局之间的关联。
我们在2020年4月12日至6月1日期间进行了一项前瞻性队列研究。纳入连续诊断为COVID-19的成年人。通过电话问卷收集NSAIDs使用信息，并对患者进行COVID-19感染结局随访，包括死亡、入院、严重程度、临床改善时间、氧气需求和住院时间。
与未使用布洛芬相比，急性使用布洛芬与更高的死亡风险无关（调整后的风险比[HR]为0.632[95%置信区间0.073 - 5.441；P = 0.6758]）。慢性使用NSAIDs也与更高的死亡风险无关（调整后的HR为0.492[95%置信区间0.178 - 1.362；P = 0.1721]）。与未使用NSAIDs的使用者相比，急性使用布洛芬与更高的入院风险无关（调整后的优势比OR为1.271；95%置信区间0.548 - 2.953）。NSAIDs使用者的临床改善时间或住院时间没有显著延长。
急性或慢性使用布洛芬和其他NSAIDs与更差的COVID-19疾病结局无关。
